Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.
作者信息
Keiffer Gina, Aderhold Kimberly L, Palmisiano Neil D
机构信息
Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States.
出版信息
Front Oncol. 2020 Dec 22;10:562219. doi: 10.3389/fonc.2020.562219. eCollection 2020.
PMID:33415071
Abstract
摘要
相似文献
[1]
Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond.
Front Oncol. 2020-12-22
[2]
[3]
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
Biomark Res. 2019-9-11
[4]
Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Best Pract Res Clin Haematol. 2019-5-12
[5]
[6]
[7]
[8]
[9]
引用本文的文献
[1]
[2]
The clinical impact of the molecular landscape of acute myeloid leukemia.
Haematologica. 2023-2-1
[3]
Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies.
Int J Mol Sci. 2022-10-22
本文引用的文献
[1]
Potential targeting of FLT3 acute myeloid leukemia.
Haematologica. 2021-3-1
[2]
[3]
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.
N Engl J Med. 2019-10-31
[4]
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Crit Rev Oncol Hematol. 2019-6-28
[5]
Availability of FLT3 inhibitors: how do we use them?
Blood. 2019-6-26
[6]
FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.
Physiol Rev. 2019-7-1
[7]
What FLT3 inhibitor holds the greatest promise?
Best Pract Res Clin Haematol. 2018-12
[8]
[9]
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med. 2017-8-3
Zotero 插件